Stakeholders have the right to know whether the industry and patient representatives on the HTA Review reference committee objected to the declaration of interest, primarily because it invalidates the input of the people and organisations they claim to represent.
It's in the name - a stakeholder with an interest has a 'stake', not a conflict
February 22, 2024 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 12, 2025 - - Latest News -
Rare Cancers Australia says election is the chance to end the ‘cancer lottery’
February 12, 2025 - - Latest News -
Specialised Therapeutics announces Thai approval of breast cancer therapy
February 12, 2025 - - Latest News -
Merck adds experienced industry executive to leadership team
February 11, 2025 - - Latest News -
Sandoz summit promotes reform to boost the use of biosimilars
February 11, 2025 - - Latest News -
AdvanCell extends collaboration with Lilly to advance novel targeted alpha therapies
February 11, 2025 - - Latest News -
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 - - Latest News